Physician profile
Muhammad Chaudhry
NPI 1194973701
$3,069.25
in general payments reported to CMS, 2019-2025
35 companies · $573 in 2025
The $573 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $222 · 2020: $706 · 2021: $159 · 2022: $308 · 2023: $636 · 2024: $465 · 2025: $573.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,674.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,673.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic Vascular, INC. | $656.96 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $329.51 | 2022-2025 | Verquvo |
| Medtronic, INC. | $209.26 | 2021-2025 | Mazor X System, Venaseal, Corevalve Evolut R |
| Impulse Dynamics (USA) INC. | $162.31 | 2022-2023 | Optimizer |
| Horizon Therapeutics Plc | $135.31 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $127.09 | 2019-2025 | Lifevest |
| Cleerly, INC. | $126.05 | 2024 | Cleerly Ischemia, Cleerly Labs |
| Scpharmaceuticals INC. | $117.38 | 2023-2025 | |
| Janssen Pharmaceuticals, INC | $116.06 | 2021-2024 | Xarelto |
| Amgen INC. | $113.66 | 2019-2025 | Repatha, Repatha |
| Novartis Pharmaceuticals Corporation | $100.22 | 2019-2023 | |
| Sanofi-Aventis U.S. LLC | $69.56 | 2022-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $64.17 | 2019-2024 | Jardiance |
| Pfizer INC. | $62.57 | 2021-2023 | |
| Astrazeneca Pharmaceuticals LP | $58.46 | 2024-2025 | Farxiga |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $50.46 | 2023-2025 | Ozempic, Rybelsus |
| Abiomed | $49.50 | 2025 | |
| Kiniksa Pharmaceuticals International, Plc | $44.59 | 2024 | Arcalyst |
| Abbott Laboratories | $39.75 | 2021-2025 | Jot Dx |
| Cardiovascular Systems INC. | $35.94 | 2020 | |
| Medicomp INC | $35.84 | 2024 | Telepatch Cardiac Monitor |
| Shockwave Medical, INC | $32.75 | 2023 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Azurity Pharmaceuticals, INC. | $32.38 | 2023-2024 | Edarbyclor, Edarbyclor |
| Edwards Lifesciences Corporation | $29.46 | 2023 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Boston Scientific Corporation | $29.30 | 2022 | |
| Kiniksa Pharmaceuticals, LTD. | $28.86 | 2023 | Arcalyst |
| Inari Medical, INC. | $28.20 | 2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| E.R. Squibb & Sons, L.L.C. | $27.01 | 2025 | Camzyos |
| Lexicon Pharmaceuticals, INC. | $26.85 | 2024 | |
| Biosense Webster, INC. | $26.19 | 2023 | Carto 3 |
| Inspire Medical Systems, INC. | $24.85 | 2025 | Inspire |
| Heartflow, INC. | $22.38 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $20.64 | 2025 | |
| Agepha Pharma Fz LLC | $19.24 | 2024 | Lodoco |
| Esperion Therapeutics, INC. | $16.49 | 2024 | Nexletol |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Muhammad Chaudhry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.